In 2023, the sales of systemic hormonal preparations in Japan stood in measurable terms specific to the year, with a strong forward momentum observed for 2024 and beyond. The forecasted data from 2024 to 2028 displays a consistent annual growth, with figures rising from 24.5 to 29 US Dollars PPP per capita. This reflects a positive year-on-year increase, with the last two years showing significant upward momentum. The compounded annual growth rate (CAGR) over the five-year forecast is a testament to this upward trend.

Future trends worth monitoring include:

Innovations in drug formulations enhancing systemic hormone therapy efficacy.
Regulatory developments impacting hormone therapy applications and market dynamics.
Shifts in consumer healthcare preferences perhaps swaying towards more integrated hormonal treatments.